HLHai-Bo Lei

Hai-Bo Lei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hai-Bo Lei has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Xiang Liu

    Department of Clinical Pharmacy, The Central Hospital of Xiangtan (The Affiliated Hospital of Hunan University)

    14 shared publications
  • Ke-Qian Chen

    Department of Clinical Pharmacy, Xiangtan Central Hospital (The Affiliated Hospital of Hunan University)

    8 shared publications
  • Zheng Liu

    Clinical pharmacy, The Central Hospital of Xiangtan (The affiliated hospital of Hunan university)

    5 shared publications
  • Nan Huang

    Clinical pharmacy, The Central Hospital of Xiangtan (The affiliated hospital of Hunan university)

    4 shared publications
  • Shu-Zhi Wang

    Institute of Pharmacy and Pharmacology, School of Pharmaceutical Sciences, University of South China, Hengyang, China

    4 shared publications
  • Renzhu Liu

    Department of Clinical Pharmacy, The Central Hospital of Xiangtan (The Affiliated Hospital of Hunan University)

    2 shared publications

Latest Publications

  • Open Access

    Clinical characteristics, management, and outcomes of nivolumab-associated pituitary toxicity: a pooled analysis of published case reports and case series

    by Zheng Liu, Nan Huang, Ronghui Li, Haibo Lei, Xiang Liu

    Objective: To summarize the clinical features, diagnosis, management, and outcomes of nivolumab-associated pituitary toxicity. Methods: We conducted a pooled analysis of published case reports and case series describing nivolumab-associated pituitary toxicity. PubMed, Embase, Web of Science Core Collection, CNKI, and Wanfang Data were searched from inception to June 8, 2026, supplemented by reference-list screening. Reports with extractable individual patient data describing nivolumab-associated hypophysitis, isolated adrenocorticotropic hormone (ACTH) deficiency, or central/secondary adrenal insufficiency were included. Combination immune checkpoint inhibitor therapy, insufficient data, and duplicate reports were excluded. Data were extracted per patient. Continuous and categorical variables are presented as median (range) and n/N (%), respectively. Results: Forty-five independent patients from 43 reports were included; 33 (73.3%) were male, and median age was 68 years (39–85). Toxicity occurred after a median of 9 nivolumab cycles (n=40; range, 1–33); 8 patients (17.8%) developed symptoms after discontinuation, with a median delay of 24 weeks (4–56). Fatigue (41/44, 93.2%), anorexia (32/45, 71.1%), and nausea/vomiting (23/44, 52.3%) predominated. Hyponatremia occurred in 24/33 patients (72.7%). ACTH was low in 38/44 patients (86.4%) and inappropriately normal in 6/44 (13.6%) despite low cortisol; basal cortisol was reduced in 43/44 (97.7%). Pituitary MRI abnormalities were reported in 11/41 patients (26.8%). Hydrocortisone was the most frequently used replacement therapy, and symptoms improved in 44/45 patients (97.8%). Among 29 patients with hormonal follow-up, 2 (6.9%) had partial ACTH–cortisol axis recovery; none had complete recovery. No recurrence was reported among six patients rechallenged with nivolumab. Conclusion: Nivolumab-associated pituitary toxicity mainly affects the ACTH–cortisol axis and may present without MRI abnormalities. Prompt assessment of cortisol, ACTH, and electrolytes is warranted in symptomatic patients.

  • Open Access

    Clinical characteristics, treatment, and outcomes of Oxaliplatin-induced immune thrombocytopenia

    by Nan Huang, Zheng Liu, Ronghui Li, Haibo Lei, Xiang Liu

    Background: Although myelosuppression is its common dose-limiting toxicity, oxaliplatin-induced immune thrombocytopenia (OITP), a rare and potentially fatal type II hypersensitivity reaction, is often misdiagnosed as ordinary myelosuppression due to insufficient clinical awareness. Methods: Relevant literature published up to December 31, 2025 were retrieved from databases including PubMed, Scopus, Embase, Web of Science, Cochrane Library, Wanfang Medical Database and China National Knowledge Infrastructure (CNKI). Cases confirmed as OITP were strictly screened for retrospective analysis. Results: Among the 40 included patients, the median age was 59 years (range, 36–83 years), with a significant female predominance (65.0%). The main primary disease was colorectal cancer (92.5%), and the most commonly used chemotherapy regimen was FOLFOX (77.5%). OITP onset was characterized by a distinct latent period, with a median time to onset of the 9th chemotherapy cycle (range, 2–28 cycles). The clinical manifestations were severe: 82.5% of patients had a platelet count drop to < 25×10 9 /L, with a median nadir of only 6×10 9 /L. Bleeding symptoms were evident in 65.0% of patients, and 52.5% of patients had accompanying systemic hypersensitivity symptoms such as fever and chills. Immunological tests showed that oxaliplatin-dependent platelet antibodies were detected in 48.4% of patients. In terms of treatment, oxaliplatin was discontinued in all patients (100%), combined with platelet transfusion (62.5%), glucocorticoids (55.0%), intravenous immunoglobulin (20.0%) and plasma exchange (12.5%). The overall recovery rate was 92.5%, with a median recovery time of 7 days, and the mortality rate reached 7.5%. Conclusions: OITP is a severe immune complication occurring after cumulative exposure to oxaliplatin, often accompanied by systemic allergic symptoms. Clinicians should be alert to sudden severe thrombocytopenia after long-term oxaliplatin administration, and permanent discontinuation of oxaliplatin is strongly advised once OITP is diagnosed. In clinical practice, glucocorticoids and platelet transfusion are the main empirical treatment options for OITP, and plasma exchange may be a potential empirical salvage intervention for patients with refractory or life-threatening OITP, while the efficacy of these treatments has not been validated by comparative data.

  • Open Access

    Pharmacokinetics of acute sertraline overdose: an observational retrospective study

    by Renzhu Liu, Qichang Xing, Zheng Liu, Wencan Li, Keqian Chen, Haibo Lei, Xiang Liu

    Background: Sertraline, a selective serotonin reuptake inhibitor is commonly prescribed for adolescent patients with depression, either as monotherapy or in combination with other treatments. Therapeutic doses typically range from 50 to 300 mg/day, whereas overdose cases generally exceed 450 mg, as observed in this study. This study aimed to characterise the pharmacokinetic profiles of sertraline in acute overdose settings and evaluate the impact of gastric lavage on drug clearance. Methods: This observational case retrospective study analysed the clinical manifestations, severity, treatment interventions, and outcomes of sertraline overdose cases. Results: The dataset comprised 16 cases of sertraline overdose. Gastric lavage was administered between 0.67 h and 12 h post-ingestion, with blood sampling commencing after lavage completion. The median ingested dose was 925 mg (range: 450–1,400 mg). Apparent elimination half-lives, estimated from two-point concentration measurements obtained 1–22 h and 27–146 h post-ingestion, ranged from 13.27 to 52.78 h (median: 24.12 h). These estimates represent post-decontamination kinetics and may not reflect true elimination half-lives due to unknown peak concentration timing. No life-threatening toxicity or severe organ dysfunction was observed. Conclusion: This study characterized post-gastric lavage sertraline concentrations in 16 adolescent intentional overdose cases. Apparent half-life estimates overlapped with therapeutic ranges, but methodological constraints, including unknown Tmax and two-point sampling, preclude definitive conclusions regarding overdose pharmacokinetics. Gastric lavage appeared well-tolerated and may reduce drug exposure, though its impact on clinical outcomes requires further study. These preliminary observations require validation in prospective studies with serial sampling.

  • Open Access

    Top 100 most-cited articles on NLRP3 (2000–2024): a retrospective analysis

    by Ke-Qian Chen, Hai-Bo Lei, Mei-Ling Huang, Xiang Liu

    Objective: This study aims to identify and analyze the top 100 most-cited articles in the NLRP3 research field to uncover research trends, key contributors, and collaborative networks, thereby providing insights into the development and future directions of NLRP3 inflammasome studies. Methods: A comprehensive search was conducted using the Web of Science and PubMed from January 2000 to December 2024. Search terms included “NLRP3” and related nomenclature. Articles were screened and sorted by citation frequency, and the top 100 were selected for detailed analysis of citations, authors, countries, institutions, journals, funding sources, and research fields. Results: These articles covered 20 publishers, 218 funds, 19 research fields, 811 authors, 25 countries, 46 journals, and 224 institutions. Among these authors, Latz E published the largest number of articles and had the highest citation frequency and the strongest co-authorship ties. Among these countries, USA published the largest number of articles and had the highest citation frequency and the strongest co-authorship ties. Among these institutions, University of Massachusetts published the largest number of articles and had the highest citation frequency and the strongest co-authorship ties. Among these journals, Nature published the largest number of articles and had the highest citation frequency and the strongest co-authorship ties. Conclusion: This retrospective analysis highlights the growing interest and interdisciplinary nature of NLRP3 inflammasome research. The USA, leading institutions, and high-impact journals play central roles in shaping the field. Future research is expected to focus on translational applications, including the development of NLRP3 inhibitors and activators, and exploring NLRP3 functions in non-immune cells.


  • Open Access

    The roles of the mtDNA-cGAS-STING axis in tumor immunity: from immune activation to immune evasion

    by Nan Huang, Zheng Liu, Haibo Lei, Xiang Liu

    In the tumor microenvironment (TME), stress-induced mitochondrial DNA (mtDNA) leakage activates the mtDNA-cyclic GMP-AMP synthase (cGAS)- stimulator of interferon genes (STING) axis, which exerts a “double-edged sword” role in tumor immunity. On the one hand, it activates the STING- interferon regulatory factor 3 (IRF3) pathway via cyclic GMP-AMP (cGAMP) synthesis by cGAS, induces type I interferons (IFN-I), enhances the cytotoxic functions of CD8 + T cells and natural killer (NK) cells as well as the antigen-presenting capacity of dendritic cells (DCs), and also promotes M1 macrophage polarization and neutrophil extracellular trap (NETs) formation, thereby driving immune activation. On the other hand, sustained activation of this axis can induce programmed cell death ligand 1 (PD-L1) expression, recruit myeloid-derived suppressor cells (MDSCs), and cause T cells exhaustion, facilitating tumor immune evasion. Targeting mtDNA stability, constructing nano-drug delivery systems, or combining with immune checkpoint blockade can reshape the tumor immune microenvironment and provide new ideas for precision immunotherapy. This article systematically summarizes the dual effects of this axis on the tumor immune microenvironment, which not only deepens the understanding of cancer immunology but also provides guidance for the research, development, and optimization of precision tumor immunotherapies, and is expected to improve patient prognosis.


  • Open Access

    Mini-review: The health benefits and applications of allicin

    by Ke-Qian Chen, Hai-Bo Lei, Xiang Liu, Wen-Jing Cao

    Garlic is a perennial plant with a long history of cultivation and medicinal use. As a valuable food additive and spice, garlic contains many nutrients and chemicals. Allicin is a key bioactive organosulfur metabolite derived from garlic bulbs. In recent years, more and more scientists have carried out research on it. This article reviews the health benefits and applications of allicin. Meanwhile, we also discussed the limitations of relevant research on allicin and look forward to the future prospects of allicin. We found that allicin is a valuable metabolite in medicine and the food field. With the deepening of allicin research, the application of allicin will have a broader prospect.


  • Open Access

    Case Report: Syndrome of inappropriate antidiuretic hormone secretion induced by pramipexole: a case report and literature review

    by Ke-Qian Chen, Xiang Liu, Hai-Bo Lei

    Pramipexole, a novel dopamine receptor agonist, is widely used in the treatment of Parkinson’s disease and related syndromes. While studies have demonstrated that pramipexole can cause various adverse reactions, primarily involving the central nervous system or gastrointestinal symptoms, there remains limited reporting on pramipexole-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH). This article analyzes and discusses a case of pramipexole-induced SIADH that occurred in our hospital. At the same time, we also summarize and discuss all current cases of pramipexole-induced SIADH. We anticipate these findings will serve as a valuable clinical reference to guide appropriate medication use.


  • Open Access

    Mitochondrial DNA in atherosclerosis research progress: a mini review

    by Zheng Liu, Nan Huang, Chan Liu, Can Wu, Ling Zhou, Xiang Liu, Haibo Lei

    Atherosclerosis (AS) is a chronic inflammatory disease that primarily affects large and medium-sized arteries and is one of the leading causes of death worldwide. This article reviews the multifaceted role of mitochondrial DNA (mtDNA) in AS, including its structure, function, release, and relationship with inflammation. Damage and release of mtDNA are considered central drivers in the development of AS, as they participate in the progression of AS by activating inflammatory pathways and affecting lipid metabolism. Therefore, therapeutic strategies targeting mtDNA and its downstream effects may provide new avenues to address this global health challenge.


  • Open Access

    The current state and trends of immunotherapy research in lung cancer: a review and bibliometric analysis

    by Yun-Hua Zheng, Li Chen, Xiang Liu, Rong-Hui Li, Hai-Bo Lei, Guang-Hui Chen

    In recent years, the integration of immunotherapy in the treatment of lung cancer has marked a significant evolution in the field. This is evidenced by the surge in the volume of scientific publications, reflecting rapid advances over time. This paper presents a bibliometric analysis of lung cancer and immunotherapy research from January 2012 to December 2022, drawing on the Web of Science literature database and using the citexs data analysis platform to examine the shifts in topic hotspots over the decade. A total of 8,722 publications were retrieved, with annual publication numbers soaring from 79 in 2012 to 2,112 in 2021. The most prolific country in terms of publication volume was China (n = 3,363, 38.56%), with The University of Texas MD Anderson Cancer Center making the most significant institutional contribution (n = 156, 1.79%). Notably, the most productive authors in this domain were Benjamin Besse and Marina Chiara Garassino, who have collectively published 35 articles to date. Predominant research themes include PD1/PDL1, clinical trials, pembrolizumab, nivolumab, and immune checkpoint inhibitors. Moreover, this paper visualizes the analysis of journals, keywords, key genes and targets, and associated diseases, aiming to provide a systematic review and a forward-looking perspective on research in lung cancer and immunotherapy. By exploring current research dynamics and hotspots and identifying areas for improvement, this study seeks to provide valuable insights for future investigations in this burgeoning field.


  • Open Access

    Dauricine: Review of Pharmacological Activity

    by Ke-Qian Chen, Shu-Zhi Wang, Hai-Bo Lei, Xiang Liu

    Background: Dauricine is an important natural organic compound in Menispermum dauricum, which often has significant biological activity. Purpose: The purpose of this review is to systemically summarize and discuss the pharmacological activity and underlying mechanisms of dauricine in recent years. Methods: Web of Science (121 articles) and PubMed databases (97 articles) were used to search for articles related to “dauricine” published from 2000 to 2024. Meanwhile, we classified the pharmacological activity of dauricine by screening these articles. Results: Emerging evidence suggests that dauricine possesses numerous pharmacological activities, including neuroprotection, anti-cancer, anti-arrhythmia, anti-inflammatory and anti-diabetes. Conclusion: Dauricine has a potential value in the treatment of many diseases. We hope that this review will contribute to therapeutic development and future studies of dauricine.